Mechanisms of action in the treatment of anxiety

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 12, 2001, Pages 10-15

  Shelton, R C ^a   Brown, L L ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BUSPIRONE; DESIPRAMINE; FLUOXETINE; MIRTAZAPINE; NEFAZODONE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ANXIETY NEUROSIS; ARTICLE; DISTRESS SYNDROME; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; TREATMENT INDICATION;

AFFECT; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; COMORBIDITY; DEPRESSIVE DISORDER; HUMANS; MODELS, PSYCHOLOGICAL; PANIC DISORDER; TREATMENT OUTCOME;

EID: 0034958162     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Biological basis of generalized anxiety disorder
2. A view on noradrenergic, hypothalamic-pituitary-adrenal axis and extrahypothalamic corticotrophin-releasing factor function in anxiety and affective disorders: The reduced growth hormone response to clonidine
3. Biological bases of anxiety
4. The noradrenergic system in pathological anxiety: A focus on panic with relevance to generalized anxiety and phobias
5. Neurobiological correlates of defensive behaviors
6. Temperament, personality, and the mood and anxiety disorders
7. Structural relationships among dimensions of the DSM-IV anxiety and mood disorders and dimensions of negative affect, positive affect, and autonomic arousal
8. Anxious depression
9. Mixed anxiety-depression and its implications for models of mood and anxiety disorders
10. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
11. Effects of psychotherapy on comorbid conditions in generalized anxiety disorder
12. Diagnostic comorbidity in panic disorder: Effect on treatment outcome and course of comorbid diagnoses following treatment
13. Testing a tripartite model, 1: Evaluating the convergent and discriminant validity of anxiety and depression symptom subscales
14. Tripartite model of anxiety and depression: Psychometric evidence and taxonomic implications
15. Testing a tripartite model, 2: Exploring the symptom structure of anxiety and depression in student, adult, and patient samples
16. The relationship of personality to mood and anxiety states: A dimensional approach
17. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety
18. Where are we going with SSRIs?
19. SSRIs and SNRIs: Broad spectrum of efficacy beyond major depression
20. New indications for antidepressants
21. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder
22. Cellular mechanisms of antidepressant drug action
23. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system?
24. The cortocosteroid receptor hypothesis of depression
25. A molecular and cellular theory of depression
26. Neural plasticity to stress and antidepressant treatment
27. Fluoxetine increases steady-state levels of preproenkephalin mRNA in rat amygdala by a serotonin dependent mechanism
28. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF)
29. Clinical and biochemical manifestations of depression: Relation to the neurobiology of stress (2)
30. Is corticotropin-releasing factor a mediator of stress responses?
31. Physiological and behavioral responses to corticotropin-releasing factor administration: Is CRF a mediator of anxiety or stress responses?
32. Presently known and possible mechanisms of action for future generations of antidepressants
33. Role of 5-HT in stress, anxiety, and depression
34. Serotonin, anxiety, and stress hormones: Focus on 5-HT receptor subtypes, species and gender differences
35. 5-HT and human anxiety: Evidence from studies using acute tryptophan depletion
36. Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors
37. The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety
38. Catecholamine regulation of the prefrontal cortex
39. Behavioral functions of nucleus accumbens dopamine: Empirical and conceptual problems with the anhedonia hypothesis
40. Blunting of reactivity of dopamine transmission to palatable food: A biochemical marker of anhedonia in the CMS model?
41. Neural correlates of attention and arousal: Insights from electrophysiology, functional neuroimaging and psychopharmacology
42. Serotonin-dopamine interaction in the rat ventral tegmental area: An electrophysiological study in vivo
43. Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists
44. Serotonin-mediated increase in prefrontal cortex dopamine release: Pharmacological characterization
45. Serotonin 5-HT2C agonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens
46. Selective blockade of serotonin 2C/2B receptors enhances dopamine release in the rat nucleus accumbens
47. Characterization of endogenous serotonin-mediated regulation of dopamine release in the rat prefrontal cortex
48. R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum
49. Role of serotonin(2A) and serotonin(2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation
50. Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats
51. Regulation of striatal dopamine release through 5-HT1 and 5-HT2 receptors
52. Activation of 5-HT2A/2C receptors within the nucleus accumbens increases local dopaminergic transmission
53. Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum
54. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area
55. Differential effects of chronic imipramine and fluoxetine on basal and amphetamine-induced extracellular dopamine levels in rat nucleus accumbens
56. Intracranial reward after Lilly 110140 (fluoxetine HC1): Evidence for an inhibitory role for serotonin
57. Effects of Lilly 110140 (fluoxetine) on self-stimulation behavior in the dorsal and ventral regions of the lateral hypothalamus in the mouse
58. Acute and chronic fluoxetine treatment decreases the sensitivity of rats to rewarding brain stimulation
59. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex
60. Augmentation strategies with serotonergic-noradrenergic combinations
61. Are two antidepressant mechanisms better than one? [Brainstorms]
62. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects
63. Basic psychopharmacology of antidepressants, pt. 1: Antidepressants have seven distinct mechanisms of action
64. Relationship of anxiety and depression